JP6328861B2 - コラーゲンスポンジ - Google Patents
コラーゲンスポンジ Download PDFInfo
- Publication number
- JP6328861B2 JP6328861B2 JP2017549842A JP2017549842A JP6328861B2 JP 6328861 B2 JP6328861 B2 JP 6328861B2 JP 2017549842 A JP2017549842 A JP 2017549842A JP 2017549842 A JP2017549842 A JP 2017549842A JP 6328861 B2 JP6328861 B2 JP 6328861B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- sponge
- absorbable
- linked
- chemically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000515 collagen sponge Substances 0.000 title claims description 78
- 108010035532 Collagen Proteins 0.000 claims description 139
- 102000008186 Collagen Human genes 0.000 claims description 139
- 229920001436 collagen Polymers 0.000 claims description 139
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 78
- 239000000835 fiber Substances 0.000 claims description 62
- 239000002002 slurry Substances 0.000 claims description 56
- 239000000243 solution Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 29
- 239000011148 porous material Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 24
- 230000006835 compression Effects 0.000 claims description 24
- 238000007906 compression Methods 0.000 claims description 24
- 230000014759 maintenance of location Effects 0.000 claims description 23
- 229920002549 elastin Polymers 0.000 claims description 20
- 102000016942 Elastin Human genes 0.000 claims description 17
- 108010014258 Elastin Proteins 0.000 claims description 17
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 210000004872 soft tissue Anatomy 0.000 claims description 17
- 241000283690 Bos taurus Species 0.000 claims description 16
- 230000007547 defect Effects 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 238000011049 filling Methods 0.000 claims description 14
- 210000004379 membrane Anatomy 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 210000004303 peritoneum Anatomy 0.000 claims description 12
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 11
- 210000000214 mouth Anatomy 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 238000005520 cutting process Methods 0.000 claims description 8
- 210000004207 dermis Anatomy 0.000 claims description 8
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 8
- 229910052753 mercury Inorganic materials 0.000 claims description 8
- 238000002459 porosimetry Methods 0.000 claims description 8
- 238000010382 chemical cross-linking Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 208000005156 Dehydration Diseases 0.000 claims description 5
- 238000010306 acid treatment Methods 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 5
- 210000003516 pericardium Anatomy 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 210000005152 placental membrane Anatomy 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 102000029816 Collagenase Human genes 0.000 description 12
- 108060005980 Collagenase Proteins 0.000 description 12
- 229960002424 collagenase Drugs 0.000 description 11
- 230000035876 healing Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000023753 dehiscence Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000193159 Hathewaya histolytica Species 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 230000007515 enzymatic degradation Effects 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000004971 Cross linker Substances 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 4
- 108010009565 Bio-Gide Proteins 0.000 description 4
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000011382 collagen catabolic process Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 102000001191 Collagen Type VIII Human genes 0.000 description 1
- 108010069526 Collagen Type VIII Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Birds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Description
B.Hafemannらは、"Journal of Materials Science: Materials in Medecine, 12 (2001)437-446"の中で、ブタ期限の加工した天然コラーゲンおよびエラスチンからなる異種メンブレンの酵素分解に対する耐性を増大するためにN−ヒドロキシスクシンイミドと一緒にカルボジイミド 1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド(EDC)を使用することは、neo−dermisを形成するためのテンプレートとして供することを意味すると開示している。
−優秀な模範SCTG(上皮下結合組織移植)と比較した、イヌの下顎骨の慢性欠陥への移植による粘膜体積獲得の測定を含む動物実験、および
−軟組織欠損充填SCTG(上皮下結合組織移植)の優秀な模範と比較した、口腔における歯科移植組織周囲の粘膜の厚さを獲得するための組織充填手順におけるその性能および安全性を調べるための臨床実験
において試験した。
(a)ブタまたはウシの腹膜または心膜を、12を超えるpHの水酸化ナトリウム溶液の塩基処理、pH 1〜3の塩化水素溶液の酸処理、水溶性有機溶媒での脱水処理および有機溶媒での脱脂処理に付し、
得た乾燥メンブレンを切削ミルで粉砕し、0.5〜2mmシーブを通して篩いにかけ、得られた粉体をpH 2.5〜3.5の酸性化水溶液に懸濁してコラーゲン繊維のスラリーを得、
(b)砕いたウシまたはブタの真皮を、水溶性有機溶媒を用いた脱水処理に付し、有機溶媒を用いて脱脂処理し、12を超えるpHの強無機塩基中で塩基処理し、pH 0〜1の強無機酸中で酸処理し、水で濯いでコラーゲン繊維を懸濁し、凍結乾燥し、乾燥したコラーゲン繊維を有機溶媒で清浄化し、清浄化した乾燥繊維をpH 3〜4の酸性化した溶液中で砕いてコラーゲン繊維のスラリーを得、
(c)(a)で得たコラーゲン繊維のスラリー3.5〜4.5部を(b)で得たコラーゲン繊維のスラリー0.5〜1.5部と混合して生じるスラリーを得、
(d)(c)で得たスラリーを凍結乾燥し、架橋剤を含む溶液中で凍結乾燥生成物を架橋し、水で洗浄して凍結乾燥し、ついで
(e)所望により、(d)で得た凍結乾燥生成物をγ照射またはX−線照射によって滅菌する。
−架橋剤がEDCである場合:
−開始温度は、緩衝液中のEDCの濃度、コラーゲンに対するEDCの比、コラーゲンに対する反応媒体の(w/w)比または緩衝液中のアルコールの%の上昇につれて、増大する。
−乾燥状態における密度は、緩衝液中のアルコールの%の上昇につれて、低下する(コラーゲンがより収縮する)。
−開始温度は、緩衝液中の架橋剤の濃度、コラーゲンに対する架橋剤(EDC+NHS)の(w/w)比、NHSに対するEDCの比、コラーゲンに対する反応媒体の(w/w)比または緩衝液中のアルコールの%の上昇につれて、増大する。
−乾燥状態における密度は、緩衝液中のアルコールの%の上昇につれて、低下する(コラーゲンがより収縮する)。
12.1kPaの圧力に49サイクル圧縮した後の最初の負荷に対する初期厚さの%およびヒステリシスの%は、プログラムTest Expert IIを用いて、機械式圧縮機械、すなわちZwick Roell製のZ2.5材料圧縮機械を用いて測定した。
−初期の高さに対する高さまたは厚さの保持は、12.1kPaへの49サイクルの圧縮後に少なくとも70%、好ましくは少なくとも80%、より好ましくは少なくとも85%であり、および
−12.1kPaへの49サイクルの圧縮の後の最初の負荷に対するヒステリシス保持は、55%未満、好ましくは45%未満である。
ヒトの身体においては、コラーゲンは、ヒト組織マトリックス−メタロプロテイナーゼ(MMP)、カテプシンおよび推定的に幾つかのセリン・プロテイナーゼによって分解される。最良の実験は、コラゲナーゼ(特にMMP−1、MMP−8、MMP−13およびMMP−18)が直接的なコラーゲン分解の最も重要な酵素であるMMPである(Lauer−Fieldsら,2002 Matrix metalloproteinases and collagen catabolism in Biopolymers−Peptide Science Section and Songら,2006 Matrix metalloproteinase dependent and independent collagen degradation in Frontiers in Bioscience)。
若年のブタからの腹膜を、機械手段によって完全に肉および脂を除去し、流水で洗浄し、ついで2%のNaOH溶液で12時間処理した。ついで、メンブレンを流水で洗浄し、0.5%のHClで酸性化した。材料をその厚さ全体を通して酸性化した(約15分)後に、pH 3.5が得られるまで材料を洗浄した。ついで、その材料を7%の塩類溶液で収縮させ、1%のNaHCO3溶液で中和し、流水で洗浄した。ついで、その材料をアセトンで脱水し、n−ヘキサンで脱脂した。
Geistlich Bio−Gide(登録商標)メンブレン(Geistlich Pharma AG,CH−6110,スイス国から入手可能)を乾燥し、0.5〜1.0 mmの台形シーブを含む切削ミルで粉砕する。コラーゲン繊維の4%(w/w)コラーゲンスラリーおよびコラーゲン繊維の6%(w/w)コラーゲンスラリーは、水に十分な量の乾燥粉末を懸濁し、10mMの塩酸でpHを2.6に調整することによって調製した。
ブタ皮をミートグラインダーで1〜20mmのピースに粉砕した。アルコールまたはケトンのような水溶性溶媒を用いて水を除去した。コラーゲン繊維は、ジクロロエタンもしくは塩化メチレンのような塩化炭化水素またはヘキサンもしくはトルエンのような非−塩化炭化水素を用いて脱脂した。溶媒を除去した後に、コラーゲンをpH 12を超える強無機塩基で6〜24時間処理し、pH 0〜1強無機酸で1〜12時間処理した。水で濯ぐことによって過剰量の酸を除去し、懸濁液を無機塩のような膨潤調整剤の存在下でコラーゲン繊維の0.5〜2%の均一な懸濁液までコロイドミルによってホモジナイズした。その懸濁液を凍結乾燥によって乾燥させ、乾燥コラーゲン繊維をアルコール、エーテル、ケトンのような異なる有機溶媒および塩化炭化水素で順次清浄化し、ついで溶媒を減圧下で1%(w/w)未満の溶媒残渣まで蒸発させた。
実施例1または実施例2で得たコラーゲン繊維の4%(w/w)コラーゲンスラリー4部を実施例3で得たコラーゲン繊維の2.5%(w/w)コラーゲンスラリー1部と混合し、8 X 25 X 25mmの型に注いだ。得られたコラーゲン繊維の3.7%スラリーを−45℃の凍結乾燥によって乾燥した。ついで、乾燥したコラーゲンスポンジを減圧下(200 mbar未満)、120℃にて24時間、脱水熱処理した。
実施例1または実施例2で得たコラーゲン繊維の6%(w/w)スラリー4部を実施例3で得たコラーゲン繊維の3.75%(w/w)スラリー1部と混合し、高さ6mmの型に注いだ。得られたコラーゲン繊維の5.55%のコラーゲンスラリーを−10℃の凍結乾燥によって乾燥した。
実施例2で得たコラーゲン繊維の6%(w/w)スラリー4部を実施例3で得たコラーゲン繊維の3.75%(w/w)スラリー1部と混合し、高さ6mmの型に注いだ。得られたコラーゲン繊維の5.55%(w/w)コラーゲンスラリーは、−10℃にて凍結乾燥した。
実施例1で得たコラーゲン繊維のスラリー4部を実施例3で得たコラーゲン繊維のスラリー1部と混合し、高さ6mmの型に注いだ。そのコラーゲンスラリーを−45℃にて凍結乾燥した。これらのスポンジは、0.05%(w/w)のグルタルアルデヒドを含むリン酸ナトリウム緩衝液(pH7.0〜7.5)中、10℃にて60分間、化学架橋した。その化学架橋コラーゲンスポンジを、水、2MのNaCl溶液および0.1MのNa2HPO4溶液で順次洗浄した。最終的に水で濯いだ後に、そのスポンジを−45℃にて凍結乾燥した。
Claims (15)
- 60〜96%(w/w)のコラーゲンおよび4〜40%(w/w)のエラスチンを含む口腔領域における軟組織欠陥充填を促進するための弾力のある吸収性の化学架橋コラーゲンスポンジであって、水銀圧入ポロシメトリーによって、10μmを超える細孔径で50〜90μmのメジアン細孔径および少なくとも80%の気孔率、45〜57℃の開始温度および乾燥状態における50〜65mg/cm3の密度を有する相互連結孔を示す化学架橋コラーゲンスポンジ。
- 46〜53℃の開始温度を示す、請求項1に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 50〜60mg/cm3の乾燥状態における密度を示す、請求項1または2に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 70〜90%(w/w)のコラーゲンおよび10〜30%(w/w)のエラスチンを含む、請求項1〜3のいずれか1項に記載の弾力のある吸収性の化学架橋スポンジ。
- 10μmよりも大きな細孔径で少なくとも90%の気孔率を示す、請求項1〜4のいずれか1項に記載の弾力のある吸収性の化学架橋スポンジ。
- グルタルアルデヒド、EDC(1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド)ならびにEDCおよびNHS(N−ヒドロキシスクシンイミド)の混合物よりなる群から選択される架橋剤を用いて得た、請求項1〜5のいずれか1項に記載の弾力のある吸収性の化学架橋スポンジ。
- 凍結乾燥および化学架橋、所望により、それにつづくγ滅菌またはX−線滅菌を含む処理によって天然起源の組織から誘導される、請求項1〜5のいずれか1項に記載の弾力のある吸収性のコラーゲン化学架橋スポンジ。
- 天然起源の組織が、ブタまたはウシの腹膜または心膜、ブタまたはウシの胎盤膜、またはブタまたはウシのSISまたは真皮を含む、請求項6または7に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 12.1kPaの圧力に49サイクル圧縮した後に初期厚さの少なくとも70%を保持する、PBS溶液によって濡らした、請求項1〜9のいずれか1項に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 12.1kPaの圧力に49サイクル圧縮した後に最初の負荷に対して55%未満のヒステリシスを保持する、PBS溶液によって濡らした、請求項1〜9のいずれか1項に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 口腔領域における移植後に、SCTG(上皮下結合組織移植)と同じ体積保持を示す、請求項1〜9のいずれか1項に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
- 請求項1〜11のいずれか1項に記載の弾力のある吸収性の化学架橋コラーゲンスポンジを調製する方法であって、以下の工程:
(a)ブタまたはウシの腹膜または心膜を、12を超えるpHの水酸化ナトリウム溶液の塩基処理、pH 1〜3の塩化水素溶液の酸処理、水溶性有機溶媒での脱水処理および有機溶媒での脱脂処理に付し、得た乾燥メンブレンを切削ミルで粉砕し、0.5〜2mmシーブを通して篩いにかけ、得られた粉体をpH 2.5〜3.5の酸性化水溶液に懸濁してコラーゲン繊維のスラリーを得、
(b)砕いたウシまたはブタの真皮を、水溶性有機溶媒を用いた脱水処理に付し、有機溶媒を用いて脱脂処理し、12を超えるpHの強無機塩基中で塩基処理し、pH 0〜1の強無機酸中で酸処理し、水で濯いでコラーゲン繊維を懸濁し、凍結乾燥し、乾燥したコラーゲン繊維を有機溶媒で清浄化し、清浄化した乾燥繊維をpH 3〜4の酸性化した溶液中で砕いてコラーゲン繊維のスラリーを得、
(c)(a)で得たコラーゲン繊維のスラリー3.5〜4.5部を(b)で得たコラーゲン繊維のスラリー0.5〜1.5部と混合して生じるスラリーを得、
(d)(c)で得たスラリーを凍結乾燥し、架橋剤を含む溶液中で凍結乾燥生成物を架橋し、水で洗浄して凍結乾燥し、ついで
(e)所望により、(d)で得た凍結乾燥生成物をγ照射またはX−線照射によって滅菌する
を含む方法。 - 架橋剤がグルタルアルデヒド(グルタルアルデヒド)、EDC(1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド)ならびにEDCおよびNHSの混合物(N−ヒドロキシスクシンイミド)よりなる群から選択される、請求項12に記載の方法。
- 工程(a)で調製したコラーゲン繊維のスラリーが2.5〜3.75(w/w)%のコラーゲンを含み、工程(b)で調製したコラーゲン繊維のスラリーが4.0〜6.0(w/w)%のコラーゲンを含む、請求項12または13に記載の方法。
- 口腔における移植組織として用いるための、請求項1〜11のいずれか1項に記載の弾力のある吸収性の化学架橋コラーゲンスポンジ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14197987.2 | 2014-12-15 | ||
EP14197987.2A EP3034103A1 (en) | 2014-12-15 | 2014-12-15 | Collagen Sponge |
PCT/EP2015/079754 WO2016096831A1 (en) | 2014-12-15 | 2015-12-15 | Collagen sponge |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017537764A JP2017537764A (ja) | 2017-12-21 |
JP6328861B2 true JP6328861B2 (ja) | 2018-05-23 |
Family
ID=52023367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017549842A Active JP6328861B2 (ja) | 2014-12-15 | 2015-12-15 | コラーゲンスポンジ |
Country Status (20)
Country | Link |
---|---|
US (2) | US9655997B2 (ja) |
EP (2) | EP3034103A1 (ja) |
JP (1) | JP6328861B2 (ja) |
KR (1) | KR101792474B1 (ja) |
CN (1) | CN106999632B (ja) |
AU (1) | AU2015367710B2 (ja) |
BR (1) | BR112017011140B1 (ja) |
CA (1) | CA2970849C (ja) |
DK (1) | DK3055000T3 (ja) |
ES (1) | ES2613672T3 (ja) |
HK (1) | HK1221668A1 (ja) |
HU (1) | HUE031528T2 (ja) |
IL (1) | IL252909B (ja) |
MX (1) | MX368544B (ja) |
PL (1) | PL3055000T3 (ja) |
PT (1) | PT3055000T (ja) |
RU (1) | RU2672593C1 (ja) |
SG (1) | SG11201704864YA (ja) |
TW (1) | TWI672155B (ja) |
WO (1) | WO2016096831A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3034103A1 (en) | 2014-12-15 | 2016-06-22 | Geistlich Pharma AG | Collagen Sponge |
EP3263144A1 (en) * | 2016-06-30 | 2018-01-03 | Jacek Zurek | A method for preparing a material for soft tissue regeneration and a material for soft tissue regeneration |
GB201615205D0 (en) * | 2016-09-07 | 2016-10-19 | Jellagen Pty Ltd | Method |
CN106421883A (zh) * | 2016-11-10 | 2017-02-22 | 武汉医佳宝生物材料有限公司 | 一种医用胶原蛋白海绵的制备方法 |
CN108714235A (zh) * | 2018-06-01 | 2018-10-30 | 陕西科技大学 | 一种基于低免疫原性胶原蛋白修饰的高生物活性普鲁兰医用薄膜及其制备方法 |
CN111388742A (zh) * | 2020-04-26 | 2020-07-10 | 无锡贝迪生物工程股份有限公司 | 一种能够缓控释放抗生素的胶原敷料及其制备方法 |
WO2022079186A1 (en) | 2020-10-15 | 2022-04-21 | Geistlich Pharma Ag | Applicator of a spongeous collagen membrane and kit comprising such applicator and membrane |
WO2022237900A1 (en) * | 2021-05-13 | 2022-11-17 | Shanghai Qisheng Biological Preparation Co., Ltd. | Derivatized or rapidly polymerizing collagen compositions for tissue augmentation containing non-resorbable or slowly resorbable polymers |
EP4209232A1 (en) * | 2022-01-06 | 2023-07-12 | Geistlich Pharma AG | Collagen device for meniscus regeneration |
CN114573861B (zh) * | 2022-03-03 | 2022-11-11 | 四川大学 | 一种泡沫及其制备方法和应用 |
CN114796608A (zh) * | 2022-05-30 | 2022-07-29 | 浙江万里学院 | 一种交联改性的三维胶原支架及其制备方法 |
CN115363988A (zh) * | 2022-09-23 | 2022-11-22 | 无锡贝迪生物工程股份有限公司 | 一种胶原面膜纸的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9400163D0 (en) * | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
AU784394B2 (en) * | 2001-04-27 | 2006-03-23 | Geistlich Pharma Ag | Method and membrane for mucosa regeneration |
EP1403304B1 (en) | 2001-05-30 | 2008-08-27 | Keiichi Miyamoto | Crosslinked elastin and processes for its production |
JP2003160506A (ja) * | 2001-08-10 | 2003-06-03 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 治療用遺伝物質のコラーゲン担体およびその方法 |
DE10157182A1 (de) | 2001-11-22 | 2003-06-05 | Matricel Gmbh | Verfahren zur Behandlung von Materialien biologischen Ursprungs und Elastin-Produkt |
US20060135921A1 (en) * | 2003-04-04 | 2006-06-22 | Wiercinski Robert A | Porous particulate collagen sponges |
US20050175659A1 (en) | 2004-02-09 | 2005-08-11 | Macomber Laurel R. | Collagen device and method of preparing the same |
DE102004063599B4 (de) * | 2004-12-30 | 2007-07-12 | Bayer Innovation Gmbh | Verkürzte Wundheilungsprozesse mittels neuartiger Faservliese |
DE102006042631A1 (de) * | 2006-09-05 | 2008-03-20 | Jotec Gmbh | Implantat und Verfahren zu seiner Herstellung |
US9248165B2 (en) * | 2008-11-05 | 2016-02-02 | Hancock-Jaffe Laboratories, Inc. | Composite containing collagen and elastin as a dermal expander and tissue filler |
JP5698680B2 (ja) * | 2009-01-16 | 2015-04-08 | ガイストリヒ・ファーマ・アクチェンゲゼルシャフトGeistlich Pharma Ag | 皮膚再生のための方法および膜 |
KR101321615B1 (ko) * | 2009-03-27 | 2013-10-23 | 가부시키가이샤 마루하 니치로 쇼쿠힝 | 엘라스틴 및 콜라겐을 사용한 가교물 및 그 용도 |
EP2654816B1 (en) | 2010-12-22 | 2015-02-11 | Geistlich Pharma AG | Bone substitute material |
CN102716517B (zh) * | 2011-03-30 | 2015-01-14 | 深圳兰度生物材料有限公司 | 一种引导组织再生膜及其制备方法 |
EP3034103A1 (en) | 2014-12-15 | 2016-06-22 | Geistlich Pharma AG | Collagen Sponge |
-
2014
- 2014-12-15 EP EP14197987.2A patent/EP3034103A1/en not_active Withdrawn
-
2015
- 2015-12-15 EP EP15808663.7A patent/EP3055000B1/en active Active
- 2015-12-15 HU HUE15808663A patent/HUE031528T2/en unknown
- 2015-12-15 CN CN201580067861.4A patent/CN106999632B/zh active Active
- 2015-12-15 KR KR1020177016143A patent/KR101792474B1/ko active IP Right Grant
- 2015-12-15 PT PT158086637T patent/PT3055000T/pt unknown
- 2015-12-15 BR BR112017011140-3A patent/BR112017011140B1/pt active IP Right Grant
- 2015-12-15 TW TW104142159A patent/TWI672155B/zh active
- 2015-12-15 ES ES15808663.7T patent/ES2613672T3/es active Active
- 2015-12-15 DK DK15808663.7T patent/DK3055000T3/en active
- 2015-12-15 SG SG11201704864YA patent/SG11201704864YA/en unknown
- 2015-12-15 PL PL15808663T patent/PL3055000T3/pl unknown
- 2015-12-15 JP JP2017549842A patent/JP6328861B2/ja active Active
- 2015-12-15 CA CA2970849A patent/CA2970849C/en active Active
- 2015-12-15 US US14/969,158 patent/US9655997B2/en not_active Ceased
- 2015-12-15 WO PCT/EP2015/079754 patent/WO2016096831A1/en active Application Filing
- 2015-12-15 RU RU2017125270A patent/RU2672593C1/ru active
- 2015-12-15 AU AU2015367710A patent/AU2015367710B2/en active Active
- 2015-12-15 MX MX2017007810A patent/MX368544B/es active IP Right Grant
-
2016
- 2016-08-18 HK HK16109911.9A patent/HK1221668A1/zh unknown
-
2017
- 2017-06-14 IL IL252909A patent/IL252909B/en active IP Right Grant
-
2019
- 2019-03-26 US US16/364,805 patent/USRE48536E1/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112017011140A2 (pt) | 2017-12-26 |
EP3055000B1 (en) | 2016-12-21 |
RU2672593C1 (ru) | 2018-11-16 |
SG11201704864YA (en) | 2017-07-28 |
WO2016096831A1 (en) | 2016-06-23 |
HK1221668A1 (zh) | 2017-06-09 |
KR20170073709A (ko) | 2017-06-28 |
CA2970849A1 (en) | 2016-06-23 |
IL252909A0 (en) | 2017-07-31 |
MX368544B (es) | 2019-10-07 |
USRE48536E1 (en) | 2021-04-27 |
AU2015367710B2 (en) | 2018-07-12 |
US9655997B2 (en) | 2017-05-23 |
BR112017011140B1 (pt) | 2020-03-24 |
DK3055000T3 (en) | 2017-02-06 |
EP3034103A1 (en) | 2016-06-22 |
CN106999632A (zh) | 2017-08-01 |
JP2017537764A (ja) | 2017-12-21 |
ES2613672T3 (es) | 2017-05-25 |
CA2970849C (en) | 2020-06-02 |
PL3055000T3 (pl) | 2017-05-31 |
MX2017007810A (es) | 2018-04-24 |
US20160166737A1 (en) | 2016-06-16 |
TW201627015A (zh) | 2016-08-01 |
PT3055000T (pt) | 2017-02-07 |
EP3055000A1 (en) | 2016-08-17 |
HUE031528T2 (en) | 2017-07-28 |
IL252909B (en) | 2018-05-31 |
AU2015367710A1 (en) | 2017-06-29 |
TWI672155B (zh) | 2019-09-21 |
KR101792474B1 (ko) | 2017-10-31 |
CN106999632B (zh) | 2018-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6328861B2 (ja) | コラーゲンスポンジ | |
JP5779249B2 (ja) | 癒着防止用医用材料及びその製造方法 | |
JP6633628B2 (ja) | 口腔粘膜を再生するためのバイオマテリアル足場材料 | |
JP6571872B2 (ja) | 再吸収可能な架橋された形状安定膜 | |
AU2013251800A1 (en) | Flowable tissue matrices | |
KR102232847B1 (ko) | 섬유화 무세포 진피 기질 및 생체적합성 고분자를 포함하는 조성물 및 이의 제조 방법 | |
TW201927277A (zh) | 乾燥植入組合物及可注射之水性植入調配物 | |
JP7467509B2 (ja) | アスコルビン酸を含有する注入可能な水性インプラント製剤 | |
DE102008013091B4 (de) | Verfahren zur Herstellung von Kollagen-Material, Kollagen-Material | |
CN111359020A (zh) | 软组织修复材料及其制备方法和应用 | |
JP2014230685A (ja) | 歯周組織形成用材料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171019 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171019 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20171019 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20171109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180403 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6328861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |